FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

	ss of Reporting Perso	n*	2. Issuer Name and Ticker or Trading Symbol STERIS CORP [STE]		tionship of Reporting Perso all applicable)	n(s) to Issuer		
Rosebrough	<u>Walter M Jr</u>			X	Director	10% Owner		
(Last) C/O 5960 HEIS	(First) LEY ROAD	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 11/02/2015	X	Officer (give title below) President & C	Other (specify below) EO		
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
MENTOR	OH	44060		X	Form filed by One Report	ing Person		
(City)	(State)	(Zip)			Form filed by More than (Person	One Reporting		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code V		Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Shares, No Par Value	11/02/2015		D		116,376 ⁽¹⁾	D	(2)	0	D	
Common Shares, No Par Value	11/02/2015		D		20,000	D	(2)	0	I	See Footnote Below. ⁽³⁾
Common Shares, No Par Value	11/02/2015		D		68,806	D	(2)	0	I	See Footnote Below. ⁽⁴⁾
Common Shares, No Par Value	11/02/2015		D		6,960	D	(2)	0	I	See Footnote Below. ⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Employee Stock Option (right to buy)	\$29.94	11/02/2015		D			18,000	(6)	05/30/2022	Common Shares, No Par Value	18,000	(6)	0	D	
Employee Stock Option (right to buy)	\$ 45.34	11/02/2015		D			50,000	(7)	05/31/2023	Common Shares, No Par Value	50,000	(7)	0	D	
Employee Stock Option (right to buy)	\$ 53.52	11/02/2015		D			119,000	(8)	05/30/2024	Common Shares, No Par Value	119,000	(8)	0	D	
Employee Stock Option (right to buy)	\$67.98	11/02/2015		D			111,000	(9)	08/10/2025	Common Shares, No Par Value	111,000	(9)	0	D	

Explanation of Responses:

1. These 116,376 Common Shares are held by the Reporting Person as Trustee of a revocable trust established for his benefit. 44,750 of these Common Shares are restricted. The restrictions on the restricted Common Shares lapse as follows: 5,000 on May 31, 2016; 6,250 on May 31, 2016; 6,250 on May 31, 2017; 4,250 on May 30, 2016; 4,250 on May 30, 2017, 4,250 on May 30, 2018, 3,625 on May 30, 2016, 3,625 on May 29, 2017, 3,625 on May 28, 2018, and 3,625 on May 28, 2019.

2. Represents shares of STERIS Corporation ("STERIS") disposed of pursuant to merger of a wholly-owned subsidiary of STERIS plc ("New STERIS") with and into STERIS surviving the merger as a wholly-owned subsidiary of New STERIS") with and into STERIS (the "Merger"), in exchange for ordinary shares of New STERIS, which was consummated simultaneous with and conditioned on New STERIS' acquisition of Synergy Health plc by commencing a "recommended offer" under English law. At the effective time of the Merger, each STERIS common share was cancelled and converted into the right to receive one New STERIS ordinary share.

3. These shares are held by the Reporting Person as Trustee of an irrevocable trust established for the benefit of the children of the Reporting Person and the Reporting Person's Spouse.

4. These shares are held by the Reporting Person's Spouse as Trustee of a revocable trust established for her benefit.

5. These shares are held by the Reporting Person as Trustee of an irrevocable trust established for the benefit of the grandchildren of the Reporting Person and the Reporting Person's Spouse.

6. This option becomes exercisable as follows: 18,000 on May 30, 2016. This option was assumed by New STERIS in the Merger and converted to an option to purchase 18,000 ordinary shares of New STERIS for \$29.94 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

7. This option becomes exercisable as follows: 25,000 on May 31, 2016 and 25,000 on May 31, 2017. This option was assumed by New STERIS in the Merger and converted to an option to purchase 50,000 ordinary shares of New STERIS for \$45.34 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

8. This option becomes exercisable as follows: 29,750 on May 30, 2016, 29,750 on May 30, 2017 and 29,750 on May 30, 2018. This option was assumed by New STERIS in the Merger and converted to an option to purchase 119,000 ordinary shares of New STERIS for \$53.52 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

9. This option becomes exercisable as follows: 27,750 on May 28, 2016, 27,750 on May 28, 2017, 27,750 on May 28, 2018 and 27,750 on May 28, 2019. This option was assumed by New STERIS in the Merger and converted to an option to purchase 111,000 ordinary shares of New STERIS for \$67.98 per share, subject to the same terms and conditions that were applicable to the original STERIS option.

Remarks:

/s/ Dennis P. Patton, Authorized Representative under Power of <u>11/02/2015</u> <u>Attorney</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.